| CASE REPORT |
|
| Year : 2020 | Volume
: 30
| Issue : 6 | Page : 424-426 |
Catastrophic antiphospholipid syndrome in immune thrombocytopenic purpura – Beyond tenuous concomitance!
Arun Joshi1, Vivek Sood1, Satish Mendonca1, Manu Dogra1, Gaurav Batta1, Rohit Tiwari2, Uday Yanamandra3
1 Department of Nephrology, Army Hospital (Research and Referral), New Delhi, India
2 Department of Nephro-Pathology, Army Hospital (Research and Referral), New Delhi, India
3 Department of Hematology, Army Hospital (Research and Referral), New Delhi, India
Correspondence Address:
Dr. Satish Mendonca
Department of Nephrology, Army Hospital (Research and Referral), New Delhi - 110 010
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijn.IJN_188_19
Significance of antiphospholipid antibodies in immune thrombocytopenic purpura is debatable and pose a diagnostic and therapeutic dilemma. Catastrophic antiphospholipid syndrome is a rare life-threatening entity, occurring in patients with antiphospholipid syndrome, usually after a triggering event. We describe an adult lady of chronic immune thrombocytopenic purpura (in remission) with antiphospholipid antibodies, who presented with rapidly progressive renal failure and had primary antiphospholipid syndrome nephropathy. The index manuscript titled exemplifies the fact that although the presence of APLA in ITP is known, however, management in the absence of clinical event remains debatable and may carry a future risk of thrombotic event/s mandating close monitoring with a high index of suspicion.
[FULL TEXT] [PDF]*
|
|
Editorial Board
